Q-omics provides the consensus-scored ZNF514 profile across patient tissues and cancer cell-line models. ZNF514 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF514 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ZNF514 RNA expression shows 21,154 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, COAD, and UVM as cancer lineages where ZNF514 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF514 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF514 survival associations across molecular data types. ZNF514 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF514 RNA expression–survival associations across cancer types. High ZNF514 expression shows unfavorable associations in ACC, LIHC, COAD and CESC, but favorable associations in READ and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF514 RNA expression.
This table summarizes ZNF514 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF514. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF514 shows higher tumor expression in COAD, LIHC, BLCA, LUAD, KIRC and CHOL. The COAD box plot shows higher ZNF514 RNA expression in tumor versus normal tissue (log2 FC = +0.792, t-test p < 0.001).
This table shows molecular features associated with ZNF514 in patient tissues and cancer cell lines. In patient samples, ZNF514 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF514 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
